Advertisement

Blog Viewer

Bevacizumab biosimilars

By Megan Stoller posted 04-29-2020 11:07

  
I'm working on a project to add bevacizumab biosimilars to our formulary due to payer driven preference. Can a patient be changed from one product to another as long as the indication is FDA approved and the physician allows it? Would there be any harm in, for example, recommending a patient be switched from Avastin to MVASI or Zirabev?

Thank you,
Megan
1 comment
64 views

Permalink

Comments

Rachel Fanti
10-15-2020 11:00

Currently, the interchange of biosimilar products is not listed in the Purple Book as an FDA approved therapeutic equivalent interchange. However, automatic substitution without prior approval from the prescriber is allowed in some states (my state of Florida is not one of these). Thus, we need prior approval from the provider to make the change. However, some institutions handle this through collaborative practice agreements. file:///C:/Users/g11906/Desktop/biosimcentral_guidelines.pdf